Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Taiho’s FGFR Inhibitor Lytgobi Grabs Conditional OK in Europe
July 6, 2023
- Insmed Japan to Capitalize on Arikayce, Pins Hopes on Brensocatib: New President
July 5, 2023
- Alarmed over Domestic Generics Biz, Sawai Group to Review Long-Term Targets
July 5, 2023
- Shionogi Files Xofluza for Pediatric Indication in Taiwan
July 5, 2023
- Chugai’s Hemlibra Launched for Hemophilia A without Inhibitors in Taiwan
July 5, 2023
- Nippon Shinyaku’s DMD Drug Gets Rare Pediatric Disease Tag in US
July 5, 2023
- Jan Stefan Scheld to Helm Nippon Boehringer Ingelheim
July 5, 2023
- Eisai CEO Confident on US Full Approval for Leqembi
July 5, 2023
- Teijin, Axcelead Seal Definitive Accord to Form Drug Discovery JV
July 4, 2023
- Chugai Is Best-Paying Japan Pharma Again in FY2022, 5 Drug Makers Top 10 Million Yen
July 4, 2023
- AstraZeneca Seeks Label Expansion for Synagis in Japan
July 4, 2023
- Kissei Adopts Iktos’ AI-Powered Drug Discovery System
July 4, 2023
- Maruho, Tsukuba Startup Ink ALDH2 Activator Deal
July 4, 2023
- 32 Pharma Execs Take Home Over 100 Million Yen in FY2022, Top 3 from Takeda: Securities Reports
July 3, 2023
- Meiji Seeks Booster Nod for COVID-19 mRNA Vaccine in Japan
July 3, 2023
- AstraZeneca Exits PhRMA in Japan after Global Decision
July 3, 2023
- Eisai Transfers Economic Rights for Breast Cancer Med to DRI
July 3, 2023
- Takeda Files Acquired Hemophilia A Therapy in Japan
July 3, 2023
- Shionogi’s Mulpleta Approved in China
July 3, 2023
- Taisho Launches 2nd Voluntary Redundancy Program
June 30, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…